VAP prevention â non-antimicrobial methods

More documents

Recommendations

Info

The UK TracMan trial N=909 Early (Day1-4) Late (>10 days) 30d mortality 30.8% 31.5% ICU LOS 13 13 Hosp LOS 33 34 Antibiotic use • Identical Sedation • Lower in early arm • Mean 6.9 vs. 9.3 days 54% of ‘late’ arm (wait & see arm) never needed a tracheostomy!
Timing of VAP onset Number of patients with VAP Average timing of tracheostomy in UK ‣ 6-month study ‣ 175 patients ‣ VAP in 56 Apostolopoulou E et al, Respir Care 2003; 48: 681-8
Page 1 and 2: Monday 6 th September 2010 London V
Page 3 and 4: 1970 - 1980’s VAP is an iatrogeni
Page 5 and 6: Pepsin - in the lungs! • Intra-tr
Page 7 and 8: Supine body position as a risk fact
Page 9 and 10: Benefits seen in ‘Drakulovic’ t
Page 11 and 12: Oropharyngeal cleansing with 0.2% c
Page 13 and 14: Draft High Impact Intervention No 5
Page 15 and 16: Silver-coated ET tubes & VAP
Page 17 and 18: Silver-coated ET tubes & VAP VAP @
Page 19 and 20: Pneumonia in intubated patients: ro
Page 22 and 23: Subglottic Secretion Drainage Tubes
Page 24 and 25: Subglottic Secretion Drainage & VAP
Page 26 and 27: Kimberly-Clark £~15 ~£6 ~£10 Cov
Page 28 and 29: Stress ulcer prophylaxis & VAP VAP/
Page 32 and 33: Tight glucose control to prevent VA
Page 34 and 35: Tight glucose control to prevent VA
Page 36 and 37: Selective Decontamination to preven

VAP prevention â non-antimicrobial methods

Create successful ePaper yourself

Delete template?

Save as template?

VAP prevention â non-antimicrobial methods